TABLE 5.
Top 15 meta-analysis of anti-PD1/PDL1 sorted by LCS.
| Title | Source | Year | LCS | GCS |
|---|---|---|---|---|
| Cancer immunotherapy efficacy and patients’ sex: a systematic review and meta-analysis | CONFORTI F, LANCET ONCOL | 2018 | 19 | 109 |
| Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis | NISHINO M, JAMA ONCOL | 2016 | 17 | 185 |
| Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis | ABDEL-RAHMAN O, EXPERT OPIN DRUG SAF | 2015 | 14 | 30 |
| Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis | ABDEL-RAHMAN O, FUTURE ONCOL | 2016 | 14 | 69 |
| Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis | LEE CK, JAMA ONCOL | 2018 | 14 | 99 |
| Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis | ABDEL-RAHMAN O, FUTURE ONCOL | 2015 | 13 | 48 |
| Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis | WANG DY, JAMA ONCOL | 2018 | 13 | 175 |
| Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis | NISHIJIMA TF, ONCOLOGIST | 2017 | 11 | 70 |
| A Network Meta-analysis Comparing the Efficacy and Safety of Anti-PD-1 with Anti-PD-L1 in Non-small Cell Lung Cancer | YOU W, J CANCER | 2018 | 10 | 16 |
| Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis | NISHIJIMA TF, CANCER TREAT REV | 2016 | 9 | 88 |
| Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis | BARROSO-SOUSA R, JAMA ONCOL | 2018 | 9 | 148 |
| Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis | ABDEL-RAHMAN O, THER ADV RESPIR DIS | 2016 | 8 | 56 |
| Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis | LEE CK, J THORAC ONCOL | 2017 | 8 | 278 |
| Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients | DE VELASCO G, CANCER IMMUNOL RES | 2017 | 8 | 106 |
| Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis | PASQUALI S, CANCER TREAT REV | 2017 | 7 | 23 |